Neurosense Therapeutics : Partners With Phasev To Optimize Upcoming Als Phase 3 Trial Using Advanced Causal Machine Learning

NeuroSense partners with PhaseV to use advanced causal machine learning in their upcoming Phase 3 trial for PrimeC as a treatment for ALS. PhaseV’s analysis predicts a high probability of success in multiple subgroups, providing important insights for study design and patient enrollment.